Eron Joseph, Orkin Chloe, Cunningham Douglas, Pulido Federico, Post Frank, Wit Stéphane De, Lathouwers Erkki, Hufkens Veerle, Jezorwski John, Petrovic Romana, Brown Kimberley, Landuyt Erika Van, Opsomer Magda, Florence E., Moutschen M., Wijngaerden E.Van, Gil I.Santos, Vente J.De, Vandekerckhove Linos, Vandercam Bernard, Brunetta Jason, Conway Brian, Klein Marina, Murphy Donald, Rachlis Anita, Shafran Stephen, Walmsley Sharon, Ajana Faiza, Cotte Laurent, Girardy P-M, Katlama Christine, Molina Jean Michel, Poizot-Martin Isabelle, Raffi Francois, Rey David, Reynes Jacques, Teicher Elina, Yazdanpanah Yazdan, Gasiorowski Jacek, Halota Waldemar, Horban Andrzej, Piekarska Anna, Witor Adam, Arribas Jose R, Perez-Valero Ignacio, Berenguer Juan, Casado Jl, Gatell Jose, Gutiérrez Félix, Galindo Maria-José, Gutierrez Maria del Mar, Iribarren José Antonio, Knobel Hernando, Negredo Eugenia, Pineda Juan A, Podzamczer Daniel, Sogorb J.Portilla, Ricart C, Rivero Antonio, Santos-Gil Ignacio, Blaxhült Anders, Flamholc Leo, Gisslén Magnus, Thalme Anders, Fehr Jan, Rauch Andri, Stoeckle Marcel, Clarke Amanda B, Gazzard Brian, Johnson Margaret, Ustianowski Andrew, Waters Laura, Bailey Justin R, Benson Paul, Bhatti Laveeza, Brar Indira, Bredeek Ulf, Brinson Cynthia, Crofoot Gordon, Dejesus Edwin, Dietz Craig, Dretler Robin, Felizarta Franco, Fichtenbaum Carl, Gallant Joel, Gathe Joseph, Hagins Debbie, Henn Sarah, Henry Wk, Huhn Gregory D, Jain Mamta, Lucasti Christopher, Martorell Claudia, Mcdonald Cheryl, Mills Anthony, Morales-Ramirez Javier, Mounzer Karam, Nahass Ronald, Olivet Hannah, Osiyemi Olayemi, Prelutsky David, Ramgopal Moti, Rashbaum Bruce, Richmond Gary, Ruane Peter, Scarsella Anthony, Scribner Anita, Shalit Peter, Shamblaw David, Slim Jihad, Tashima Karen, Voskuhl Gene, Ward Douglas J, Wilkin Aimee. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. Antiviral Research. 2019;170:104543.